Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bladder cancer chemotherapy practice study].

Christine Clippe1, Sébastien Clippe, Delphine Yzebe

  • 1Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France. christine.clippe@chu-lyon.fr

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perinatal insights into human T-lymphotropic virus 1 in western French Guiana: Unmasking a silent disease.

European journal of obstetrics, gynecology, and reproductive biology·2026
Same author

Adjusted Comparison of First-line Enfortumab Vedotin Plus Pembrolizumab Versus Platinum-based Chemotherapy ± Avelumab Maintenance for the Treatment of Locally Advanced/Metastatic Urothelial Carcinoma.

European urology oncology·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Cancer immunology, immunotherapy : CII·2026
Same author

Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.

Frontiers in oncology·2026
Same journal

["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Role of nurses specializing in oncology to support the care journey for patients with penile cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Pre- and post-prostatectomy rehabilitation by the certified nurse-urologist pair (REHAB): Feasibility study].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Genitourinary complications after pelvic radiotherapy: Diagnosis and management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

[Male contraception].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
See all related articles

Chemotherapy for invasive bladder cancer showed limited efficacy and high toxicity in a retrospective study. Careful consideration of the benefit-risk ratio is essential for treatment decisions.

Area of Science:

  • Oncology
  • Urothelial Carcinomas
  • Cancer Treatment

Context:

  • Chemotherapy is a standard treatment for invasive bladder cancer.
  • Treatment protocols require ongoing evaluation in real-world clinical practice.

Purpose:

  • To evaluate the practice of chemotherapy for invasive bladder cancer at a single cancer center.
  • To assess the efficacy and toxicity of adjuvant and metastatic chemotherapy regimens.

Summary:

  • This retrospective study analyzed 104 patients with invasive bladder cancer treated between 1994 and 2000.
  • Adjuvant chemotherapy (MVAC regimen) showed a 60% relapse rate and 12-month median recurrence-free survival.
  • For metastatic disease, chemotherapy achieved a 36% objective response rate and 10-month median survival, with 21% febrile neutropenia incidence.

Related Experiment Videos

Impact:

  • Findings indicate that while chemotherapy aligns with large-scale trial results, its clinical benefit-risk ratio necessitates careful consideration due to significant toxicity.
  • Highlights the need for optimizing chemotherapy protocols through prospective studies and practice-based evidence.